Working… Menu

Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03604198
Recruitment Status : Recruiting
First Posted : July 27, 2018
Last Update Posted : July 27, 2018
Information provided by (Responsible Party):
Corcept Therapeutics

Brief Summary:
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

Condition or disease Intervention/treatment Phase
Cushing Syndrome Drug: relacorilant Phase 2

Detailed Description:

This study is designed to allow continued therapy with relacorilant, a potent, selective glucocorticoid receptor (GR) antagonist in patients who have successfully completed participation of a Corcept-sponsored study of relacorilant (referred to as the "parent" study). Patients may qualify to enter this extension study if they complete their last treatment visit in their parent study and in the Investigator's opinion will benefit from continued treatment.

Once-daily dosing with relacorilant may continue for patients who receive clinical benefits (as judged by the Investigator) until relacorilant is commercially or otherwise available or the study is stopped by the Sponsor. A patient's dose may be maintained, reduced, or increased based on individual response and tolerability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome
Actual Study Start Date : May 7, 2018
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Arm Intervention/treatment
Experimental: relacorilant (CORT125134) Drug: relacorilant
CORT125134 is supplied as capsules for oral dosing.
Other Name: CORT125134

Primary Outcome Measures :
  1. Long-term safety of relacorilant [ Time Frame: 36 months ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  2. Long-term safety of relacorilant [ Time Frame: 36 Months ]
    Changes in size from baseline in pituitary tumors based on magnetic resonance imaging (MRI) scans in patients with Cushing disease as measured by volume in cc

Secondary Outcome Measures :
  1. Changes from baseline in the Glycated hemoglobin (HbA1c) [ Time Frame: 36 Months ]
    in patients with diabetes mellitus (DM) or glucose intolerance

  2. Changes from baseline in systolic and diastolic blood pressure (BP) [ Time Frame: 36 Months ]
    By ambulatory BP measurements (ABPM) in patients with uncontrolled hypertension (HTN)

  3. Changes from baseline in Physician's Global Assessment of Disease Severity [ Time Frame: 36 Months ]
    On a scale of 1 to 9 (where 1 = absent and 9 = incapacitating)

  4. Changes from baseline in weight [ Time Frame: 36 Months ]
    measured in Kg

  5. Changes from baseline in waist circumference [ Time Frame: 36 Months ]
    measured in cm

  6. Changes in baseline in quality-of-life [ Time Frame: 36 Months ]
    Based on Cushing quality of life questionnaire 0 (worst) to 100 (best)

  7. Changes in baseline in sex steroid hormone [ Time Frame: 36 Months ]
    Testosterone and estradiol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Major Inclusion Criteria:

    • Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome with at least 80% compliance with the dosing schedule.
    • According to the Investigator's opinion will benefit from continuing treatment with relacorilant

Exclusion Criteria:

  • Major Exclusion Criteria:

    • Premature discontinuation from a relacorilant parent study.
    • Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
    • Has poorly controlled hypertension
    • Has Stage ≥ 4 renal failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03604198

Layout table for location contacts
Contact: Clinical Trial Lead for 452 Study 650-327-3270

Layout table for location information
United States, Florida
Not Provided Recruiting
Fort Lauderdale, Florida, United States, 33312
United States, Indiana
Not Provided Recruiting
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Corcept Therapeutics
Layout table for investigator information
Study Director: Andreas G Moraitis, MD Corcept Therapeutics

Layout table for additonal information
Responsible Party: Corcept Therapeutics Identifier: NCT03604198     History of Changes
Other Study ID Numbers: CORT125134-452
First Posted: July 27, 2018    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corcept Therapeutics:
Cushing Syndrome
Cushing Disease
Type 2 Diabetes
Impaired Glucose Intolerance
Adrenal Corticotrophic Hormone (ACTH)
Adrenocortical Carcinoma
Primary Pigmented Nodular Adrenal Disease (PPNAD)
Moon Facies
Dorsocervical Fat Pad
Adrenal Adenoma
Adrenal Carcinoma
Adrenal Autonomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Cushing Syndrome
Pathologic Processes
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases